Business, energy, technology, markets and global industry news from Business News Today

Lu AG13909

PharmaDeviceNews Lu AG13909
Endogenous Cushing’s syndrome research advances as the US Food and Drug Administration grants orphan drug designation to Lundbeck’s asedebart, supporting development of a novel ACTH-neutralising therapy for patients with rare endocrine disorders. Representative image.
Pharma & Biotech

Lundbeck wins FDA Orphan Drug status for asedebart in endogenous Cushing’s syndrome

FDA grants orphan status to Lundbeck’s asedebart for endogenous Cushing’s syndrome as Phase 2 testing examines direct ACTH neutralization.

Read More